Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avandia Safety Rhetoric Ramps Up Ahead Of Advisory Committee Review

Executive Summary

Participants in the ongoing safety debate over GlaxoSmithKline's Avandia (rosiglitazone) are refining their arguments ahead of the July 13-14 joint FDA advisory committee meeting on the troubled thiazolidinedione's future

You may also be interested in...



Pradaxa Bleeding Risk Gets Deeper FDA Scrutiny In Mini-Sentinel Project

A 2012 Sentinel study didn’t find any problems, but FDA wants a closer look now that the dataset has grown.

Anatomy Of The Avandia Decision: FDA’s Woodcock Splits The Difference Between OND, OSE Views

In deciding to keep GlaxoSmithKline PLC’s Avandia on the market, while also heavily restricting its use, FDA Center for Drug Evaluation and Research Director Janet Woodcock split the difference between opposing recommendations from the Office of New Drugs and Office of Surveillance and Epidemiology.

Anatomy Of The Avandia Decision: FDA’s Woodcock Splits The Difference Between OND, OSE Views

In deciding to keep GlaxoSmithKline PLC’s Avandia on the market, while also heavily restricting its use, FDA Center for Drug Evaluation and Research Director Janet Woodcock split the difference between opposing recommendations from the Office of New Drugs and Office of Surveillance and Epidemiology.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel